Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Total Energy Expenditure in Infants and Children With Moderate to Severe Cystic Fibrosis
This study is ongoing, but not recruiting participants.
Study NCT00006273   Information provided by National Center for Research Resources (NCRR)
First Received: September 11, 2000   Last Updated: June 23, 2005   History of Changes

September 11, 2000
June 23, 2005
June 1996
 
 
 
Complete list of historical versions of study NCT00006273 on ClinicalTrials.gov Archive Site
 
 
 
Study of Total Energy Expenditure in Infants and Children With Moderate to Severe Cystic Fibrosis
Study of Total Energy Expenditure in Infants and Children With Moderate to Severe Cystic Fibrosis

OBJECTIVES: I. Compare the resting energy expenditure using respiratory calorimetry in infants and children with moderate to severe cystic fibrosis versus age matched healthy controls.

II. Determine the total energy expenditure and energy spent on physical activity using the doubly labeled water method in these patient populations.

PROTOCOL OUTLINE: Patients and healthy controls receive an oral dose of doubly labeled water following initial urine collection on day 1. Patients undergo additional urine collection at 4-6 hours following doubly labeled water consumption and then daily for 7 days.

Additionally, at the beginning of the study, patients and healthy controls undergo respiratory calorimetry over approximately 45 minutes at rest, starting approximately 2-3 hours after the last meal consumption and last use of aerosol bronchodilators (if required).

 
Observational
Natural History
Cystic Fibrosis
 
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Active, not recruiting
60
 
 

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

  • Diagnosis of cystic fibrosis (CF) by two positive sweat tests No exacerbations of present condition within past 2 months FEV1 less than 50% of predicted No other uncorrected lung disease No requirement for supplemental oxygen

OR

  • Healthy (control group) Age matched to CF patients No preexisting lung disease Clinically well No hospitalizations within past 6 months

--Prior/Concurrent Therapy--

  • Concurrent pancreatic enzyme supplementation for CF required Clinically stable on current medications (CF patients)

--Patient Characteristics--

  • Age: Birth to 12 months 6 to 10 years
  • Cardiovascular: No major cardiovascular problems (CF patients) No preexisting heart disease (control group)
  • Pulmonary: See Disease Characteristics
  • Other: No chromosomal abnormalities (CF patients) No acute infection (CF patients) No diabetes mellitus (both groups)
Both
up to 10 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00006273
 
NCRR-M01RR00750-9040, IU-9509-20
National Center for Research Resources (NCRR)
Indiana University School of Medicine
Study Chair: Catherine A. Leitch Indiana University
National Center for Research Resources (NCRR)
December 2003

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP